Penghua CSI Chinese Medicine ETF(159647) rises 2.93%, with a share increase of 13.50 million units over the past 3 months
NewTimeSpace (newtimespace.com) News, as of 14:38 on July 1, 2026, Penghua Traditional Chinese Medicine ETF (159647) rose 2.93%, with the latest price at 0.84 yuan.
In terms of liquidity, Penghua Traditional Chinese Medicine ETF recorded an intraday turnover rate of 1.86% and a trading volume of 24.1864 million yuan. Over a longer time frame, as of June 30, the ETF's average daily trading volume over the past year reached 30.4902 million yuan.
In terms of scale, Penghua Traditional Chinese Medicine ETF saw a significant increase of 537 million yuan in scale over the past year, with the new scale increase ranking 1/4 among comparable funds. (Data source: Wind)
In terms of shares, Penghua Traditional Chinese Medicine ETF experienced a significant increase of 13.50 million units in share count over the past three months, with the new share increase ranking 2/4 among comparable funds. (Data source: Wind)
Data shows that leveraged funds are continuously positioning. The latest margin financing purchase amount of Penghua Traditional Chinese Medicine ETF reached 1.2123 million yuan, with the latest margin financing balance standing at 22.0464 million yuan. (Data source: Wind)
From the perspective of return capability, as of June 30, 2026, since its inception, Penghua Traditional Chinese Medicine ETF achieved a highest single-month return of 16.26%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 20.28%, and an average return of 4.98% in up months. As of June 30, 2026, the ETF's annualized excess return over its benchmark for the past three months was 3.83%, ranking 1/4 among comparable funds.
In terms of drawdown, as of June 30, 2026, Penghua Traditional Chinese Medicine ETF recorded a drawdown of 0.06% relative to its benchmark since the beginning of the year, the smallest drawdown among comparable funds.
In terms of fees, Penghua Traditional Chinese Medicine ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%, the lowest fee rates among comparable funds.
In terms of tracking accuracy, as of June 30, 2026, the one-year tracking error of Penghua Traditional Chinese Medicine ETF was 0.047%, achieving the highest tracking accuracy among comparable funds.
From a valuation perspective, the latest price-to-earnings (PE-TTM) ratio of the CSI Traditional Chinese Medicine Index, which Penghua Traditional Chinese Medicine ETF tracks, is only 19.33 times, standing at the 0.78% percentile over the past year. This means the valuation is lower than over 99.22% of the time in the past year, placing it at a historical low.
Penghua Traditional Chinese Medicine ETF closely tracks the CSI Traditional Chinese Medicine Index. The CSI Traditional Chinese Medicine Index selects the securities of listed companies whose businesses involve the production and sale of traditional Chinese medicine as index constituents, in order to reflect the overall performance of traditional Chinese medicine concept listed companies.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HK shares Newly Listed Stocks Tracking Weekly Report: B&K CORP-B Leads with 68% Weekly Gain; INNOGEN-B Down Over 45% Cumulatively in Two Weeks Since Lock-up Expiry - 20260821
- METIS TECHBIO-P (07666.HK): Added as Hang Seng Composite Index Constituent, Effective 7 September
- SUNSHINE OIL (02012.HK): Subsidiary Holds 40% Stake in New Joint Venture to Build 6,000P Computing Power Centre
- CH GENERAL EDU (02175.HK): Target Company Unlikely to Meet 2026 Net Profit Target; Agreement in Principle to Reduce Acquisition Consideration
- PINESTONE (00804.HK): Net Proceeds of HKD 24.2 Million from Placing for Virtual Asset Licence Application and AI Application Expansion